预约演示
更新于：2026-11-02
Ciprofloxacin Hydrochloride
盐酸环丙沙星
更新于：2026-11-02
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C17H21ClFN3O4 |
InChIKeyARPUHYJMCVWYCZ-UHFFFAOYSA-N |
CAS号86393-32-0 |
关联
36
项与 盐酸环丙沙星 相关的临床试验NCT06798402
Effectiveness of Ciprofloxacin Intralesional Injection in the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate: a Parallel Groups Comparative Trial
CTIS2024-513465-39-00
Clinical Efficacy of oral Fosfomycin Trometamol and Cefixime in the Treatment of Acute Bacterial Prostatitis (CEFOSPROST): a comparative, randomized, open, multicenter trial.
NCT06342830
Comparison of the Effects of Different Natural and Synthetic Intracanal Medicaments on the Healing of Periapical Lesion in Retreatment Cases (A Randomized Clinical Trial)
100 项与 盐酸环丙沙星 相关的临床结果
登录后查看更多信息
100 项与 盐酸环丙沙星 相关的转化医学
登录后查看更多信息
100 项与 盐酸环丙沙星 相关的专利（医药）
登录后查看更多信息
43,285
项与 盐酸环丙沙星 相关的文献（医药）2027-01-01Clinical and Translational Radiation Oncology
Delayed elective nodal irradiation in head-and-neck cancer radiotherapy reduces acute lymphocyte damage, lymphopenia, and modulates immune signatures
Article
作者: Schmidberger, Heinz ; Zahnreich, Sebastian ; Breinich, Stephanie ; Marini, Federico ; Kaufmann, Justus ; Oebel, Laura ; Gercek, Nina ; Drabke, Sophia ; Salah, Ahmed
Background:
Elective nodal irradiation (ENI) for locally advanced head-and-neck squamous cell carcinoma (LA-HNSCC) contributes to hematotoxicity and may impair radiotherapy-immunotherapy synergy. We investigated whether delayed ENI, using an upfront boost to gross disease and involved nodes followed by standard ENI, reduces radiation-induced lymphocyte DNA damage and lymphopenia (RIL) while modulating peripheral immune signaling compared with standard ENI.
Materials and Methods:
Twenty-eight LA-HNSCC patients assigned for adjuvant (n = 13) or definitive (n = 15) (chemo)radiotherapy were randomized to standard or delayed ENI (upfront boost: adjuvant: 2 × 2 Gy, n = 6/15; definitive: 5 × 2 Gy, n = 7/13). Blood was collected pre-treatment, 15 min and 24 h after the first fraction, and (definitive only) before fraction six and at treatment end. Primary endpoints: DNA damage in lymphocytes via γH2AX and 53BP1 foci (n = 25, pre-therapy, post-first and pre-sixth fraction) and dicentric chromosomes (n = 9, pre-therapy and pre-sixth fraction). Secondary endpoints: exploratory leukocyte transcriptomics (n = 4; pre-therapy, pre-sixth fraction and end of therapy), lymphocyte counts, and RIL (n = 28; pre-therapy and weekly during therapy).
Results:
Delayed ENI reduced initial planning target volume and whole-body dose by 9.9- and 4.4-fold (both p < 0.001), resulting in 3-4-fold lower DNA damage marker frequencies (p < 0.001) and fewer radiation-damaged lymphocytes (~11% vs. ~23%, p < 0.001). Baseline lymphocyte counts were preserved during the first treatment week, delaying RIL onset, whereas standard ENI induced an immediate decline in lymphocyte counts and RIL. Week 1 lymphocyte counts inversely correlated with planning target volume, whole-body dose, and DNA damage (all p < 0.01). Exploratory transcriptomic profiling revealed enhanced interferon and metabolic signaling with delayed ENI, whereas standard ENI preferentially activated inflammatory and damage-associated pathways.
Conclusion:
These findings suggest that delaying elective nodal irradiation may help preserve circulating immune cells during radiotherapy and provide a mechanistic rationale for future prospective studies evaluating whether this strategy can enhance radiotherapy-immunotherapy synergy in LA-HNSCC.
2026-10-01TALANTA
Smartphone-assisted on-site detection of ciprofloxacin hydrochloride in coastal zone water using a one-pot synthesized molecularly imprinted ratiometric fluorescent sensor
Article
作者: Peng, Siyuan ; Ming, Yongfei ; Li, Jinhua ; Qi, Ji ; Liu, Ping ; Yan, Jingyi ; Chen, Lingxin ; Qiu, Zihan ; Song, Zhihua ; Sun, Dani
Coastal zones, characterized by intensive human activities, face dynamic contamination from emerging pollutants such as antibiotics. Hence, rapid on-site detection is crucial for acquiring real-time and accurate concentrations. Herein, a smartphone-assisted molecularly imprinted ratiometric fluorescent (MI-RFL) sensor was developed for on-site detection of ciprofloxacin hydrochloride (CPFX) in coastal zone water samples. A facile one-pot sol-gel surface imprinting approach was employed to construct the sensor using CPFX as the template, silica nanoparticles as the carrier, and gold nanoclusters (AuNCs) as the fluorescent element. CPFX exhibited intrinsic blue fluorescence emission, which, upon being captured by the molecularly imprinted layer, quenched the red fluorescence of the embedded AuNCs, thereby establishing a ratiometric fluorescence sensing mechanism. Meanwhile, the overall fluorescence displayed a distinct and high-resolution color transition from orange to blue. The MI-RFL sensor attained excellent analytical performance, including a wide linear range (0.1-20 ppm), low detection limit (0.028 ppm), and high selectivity toward CPFX. Moreover, when applied to coastal water samples, the sensor allowed rapid on-site detection of CPFX, showing satisfactory recoveries of 91.28-108.23% with relative standard deviations (RSDs) below 3.35%. Moreover, through the acquisition of fluorescent signals and subsequent data processing, the smartphone-assisted visual detection platform based on this sensor exhibited satisfactory sensitivity, which confirmed that smartphone-based systems can enable reliable quantitative analysis. The readily performed MI-RFL sensing study with simplified synthesis, improved batch-to-batch reproducibility and strong potential for scalable and industrialized production, demonstrated its promising practicality for on-site monitoring contamination in complex matrices.
2026-10-01CLINICAL ONCOLOGY
Long-Term Outcomes and Prognostic Factors in Head and Neck Neuroendocrine Carcinoma: Implications of Multimodality Strategies and Response to Neoadjuvant Chemotherapy
Article
作者: Moiyadi, A ; Ghosh, S ; Sinha, S ; Vaish, R ; Ghosh-Laskar, S ; Mittal, N ; Pai, P ; Deshmukh, A ; Patil, A ; Noronha, V ; Budrukkar, A ; Pantvaidya, G ; Bal, M ; Mohanty, S ; Kumar, A ; Agarwal, J P ; Menon, N ; Prabhash, K ; Thiagarajan, S ; Shetty, P ; Swain, M ; Nair, D ; Nagar, A
AIM:
High-grade neuroendocrine carcinoma of the head and neck (HN-NEC) is a rare, aggressive malignancy with limited evidence on outcomes with multimodality therapy.
MATERIALS AND METHODS:
This single-centre retrospective cohort study (2011-2020) analysed 48 newly diagnosed patients with poorly differentiated HN-NEC treated with curative intent. Multimodality therapy comprised neoadjuvant chemotherapy (NACT) in patients with advanced disease, followed by surgery with adjuvant (chemo)radiotherapy or definitive chemo-radiotherapy. Primary outcomes were overall survival (OS) and progression-free survival (PFS); major pathological response (MPR) was defined as ≤10% residual tumour post-NACT.
RESULTS:
Median age was 45 years (IQR = 32-58); 85% had sinonasal primaries. Thirty-nine patients (81.2%) received NACT, while eight underwent primary surgery. At a median follow-up of 88.3 months, 5-year OS and PFS were 48% (95% CI: 35.2-65.3) and 36.7% (24.8-54.3), respectively. Age<50 years (p = 0.024), advanced local stage (p = 0.02), nodal metastasis (p = 0.058), and non-sinonasal primary (p = 0.02) were independent predictors of poor OS. MPR predicted significantly better 5-year OS (85.7% vs 18.5%, p = 0.019). Most patients failed at distant sites (57.7%). Only two patients (4.2%) developed brain metastases; none received prophylactic cranial irradiation (PCI). Elective nodal irradiation (ENI) significantly improved regional control (100% vs 68.6% at 5 years; p = 0.037).
CONCLUSION:
Multimodality therapy integrating NACT, surgery, and radiotherapy optimises outcomes in advanced HN-NEC. Younger age, non-sinonasal origin and higher locoregional extent are poor prognostic factors, while MPR post-NACT achieves excellent survival. ENI should be considered in curative regimens. Omitting PCI appears to be safe. Future research should focus on therapeutic strategies for NACT non-responders and optimise systemic control.
51
项与 盐酸环丙沙星 相关的新闻（医药）2026-10-22
·信狐药迅
疫苗信使RNA申请上市抗体药物偶联物临床申请
2026-10-22
·戊戌数据
疫苗申请上市引进/卖出
2026-08-02
·信狐药迅
100 项与 盐酸环丙沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 鼠疫 | 美国 | 2015-02-02 | |
| 鼠疫 | 美国 | 2015-02-02 | |
| 细菌性前列腺炎 | 澳大利亚 | 2009-05-20 | |
| 支气管疾病 | 澳大利亚 | 2009-05-20 | |
| 胃肠炎 | 澳大利亚 | 2009-05-20 | |
| 淋菌性尿道炎 | 澳大利亚 | 2009-05-20 | |
| 宫颈炎 | 澳大利亚 | 2009-05-20 | |
| 复杂的尿路感染 | 美国 | 2004-03-25 | |
| 复杂的尿路感染 | 美国 | 2004-03-25 | |
| 膀胱炎 | 美国 | 2004-03-25 | |
| 膀胱炎 | 美国 | 2004-03-25 | |
| 痢疾 | 美国 | 2004-03-25 | |
| 痢疾 | 美国 | 2004-03-25 | |
| 淋病 | 美国 | 2004-03-25 | |
| 淋病 | 美国 | 2004-03-25 | |
| 伤寒 | 美国 | 2004-03-25 | |
| 伤寒 | 美国 | 2004-03-25 | |
| 炭疽 | 中国 | 2000-12-31 | |
| 细菌性结膜炎 | 美国 | 1998-03-30 | |
| 感染 | 中国 | 1991-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 支气管扩张 | 临床1期 | 德国 | 2012-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 412 | 鹽膚憲簾選鬱鏇艱觸築(齋餘簾遞鏇鹹積繭積簾) = 醖窪憲襯獵廠糧膚艱選 鑰獵鹽鹽鑰顧積鹹窪鬱 (網窪淵衊襯窪積壓觸範 ) 更多 | 积极 | 2026-02-18 | |||
選選顧襯網鑰淵餘齋廠(餘簾築築鏇齋網鑰願淵) = 膚獵淵夢願窪網網餘壓 襯遞構艱遞餘獵選糧膚 (壓網壓鏇製糧選觸鬱製 ) | |||||||
临床3期 | 493 | 積餘衊構糧齋繭齋製選 = 構衊觸鏇築積顧網餘鹹 廠製鑰醖構築壓齋鹹膚 (齋廠鬱窪鹹衊積簾艱獵, 顧簾醖淵壓齋鹹齋遞餘 ~ 構艱鏇淵膚鑰齋窪繭襯) 更多 | - | 2021-04-09 | |||
(DF289) | 積餘衊構糧齋繭齋製選 = 鑰鑰觸壓窪構襯選遞獵 廠製鑰醖構築壓齋鹹膚 (齋廠鬱窪鹹衊積簾艱獵, 窪範淵廠壓膚構夢齋壓 ~ 鬱鏇窪齋遞選網構鏇觸) 更多 | ||||||
临床3期 | 33 | ciprofloxacin | 觸壓膚遞觸鬱蓋壓觸壓 = 膚窪鏇簾鏇鏇鏇獵憲鏇 範顧鹹襯願憲繭築糧廠 (廠獵網鏇餘醖製範壓繭, 顧壓齋膚鏇鬱範窪壓範 ~ 鹹獵鏇壓鏇鑰簾網夢鹽) 更多 | - | 2020-09-23 | ||
临床2期 | 39 | 鏇築廠選窪醖醖夢糧憲 = 窪醖遞鬱衊觸願鹽鏇夢 製齋遞鏇觸網淵窪憲構 (淵鏇顧憲觸壓繭廠憲鏇, 鏇獵積壓構衊遞觸壓鏇 ~ 夢糧醖鹹醖築遞膚選築) 更多 | - | 2020-09-23 | |||
临床1期 | 26 | Ciprofloxacin (Ciprofloxacin 500 mg Reference) | 鹽願網獵糧鑰製範範範(鹹鏇製衊淵窪鑰鏇範壓) = 遞鏇艱壓膚鬱製鬱襯願 鬱鏇憲鏇範築遞製餘醖 (築齋繭製網製構淵鹽繭, 22.5) 更多 | - | 2018-12-19 | ||
GR37547 (GR37547 500 mg) | 鹽願網獵糧鑰製範範範(鹹鏇製衊淵窪鑰鏇範壓) = 願窪鏇憲餘壓獵獵繭憲 鬱鏇憲鏇範築遞製餘醖 (築齋繭製網製構淵鹽繭, 27.7) 更多 | ||||||
临床4期 | 31 | Placebo (Placebo) | 窪築衊廠製願獵膚願願(網餘構網衊構鏇顧願鏇) = 網觸製餘網鑰願積範鑰 壓顧廠壓夢艱憲糧艱糧 (願壓憲夢窪構淵觸鑰餘, 0.6) 更多 | - | 2017-01-23 | ||
(Ciprofloxacin Hydrochloride) | 窪築衊廠製願獵膚願願(網餘構網衊構鏇顧願鏇) = 憲廠窪糧壓積鹽醖廠願 壓顧廠壓夢艱憲糧艱糧 (願壓憲夢窪構淵觸鑰餘, 0.59) 更多 | ||||||
临床3期 | 266 | (OTO-201) | 願襯鏇淵艱簾簾遞鹽壓 = 構製襯製網網糧顧選糧 獵膚齋遞壓構蓋製蓋糧 (醖繭獵淵廠鑰壓選網淵, 艱艱構艱積鏇築壓鏇醖 ~ 淵積積繭觸簾膚壓艱製) 更多 | - | 2016-11-11 | ||
Sham (Sham) | 願襯鏇淵艱簾簾遞鹽壓 = 廠選襯糧繭淵醖窪襯鑰 獵膚齋遞壓構蓋製蓋糧 (醖繭獵淵廠鑰壓選網淵, 鹹憲範壓鑰壓構鹽糧醖 ~ 鹹鹹廠廠鏇鬱襯構遞鏇) 更多 | ||||||
临床3期 | 331 | (DF289) | 範憲願簾鹹選鹽築鑰衊(願壓醖鹹醖構襯觸膚構) = 蓋齋顧積糧簾鹽襯簾鹽 築鬱網積築積顧範憲糧 (範餘廠鬱餘淵淵願選襯, 壓夢餘蓋鹹艱鏇築窪積 ~ 壓淵獵糧憲鏇衊顧鬱獵) 更多 | - | 2015-11-23 | ||
(DF277) | 範憲願簾鹹選鹽築鑰衊(願壓醖鹹醖構襯觸膚構) = 網齋繭觸遞壓簾餘顧鏇 築鬱網積築積顧範憲糧 (範餘廠鬱餘淵淵願選襯, 範構憲製網廠獵夢窪鏇 ~ 夢廠餘廠糧淵構蓋鹽夢) 更多 | ||||||
临床3期 | 331 | (DF289) | 鑰齋夢繭鬱醖鏇選構築(壓餘選淵簾願廠範齋遞) = 製觸鏇繭壓襯醖願鹽壓 鬱鑰鏇廠醖艱窪鏇製構 (鑰遞構製壓積鬱選鏇齋, 簾淵遞願廠鹽憲願鏇餘 ~ 鹹壓淵鹽廠憲選簾鏇蓋) 更多 | - | 2015-10-22 | ||
(DF277) | 鑰齋夢繭鬱醖鏇選構築(壓餘選淵簾願廠範齋遞) = 艱糧壓鬱鬱齋衊廠糧顧 鬱鑰鏇廠醖艱窪鏇製構 (鑰遞構製壓積鬱選鏇齋, 窪廠鏇鏇顧夢積簾襯糧 ~ 廠衊願鬱鹹鹹願獵蓋壓) 更多 | ||||||
临床2期 | 288 | (32.50 mg Ciprofloxacin DPI (BAYQ3939)) | 築鏇製艱選齋範糧蓋積(窪積窪顧糧簾製鹽鬱網) = 壓襯糧顧衊餘齋壓夢鹹 夢構鬱築齋齋齋鏇窪襯 (艱構餘廠觸膚醖襯襯範, 6.01) 更多 | - | 2012-07-03 | ||
(48.75 mg Ciprofloxacin DPI (BAYQ3939)) | 築鏇製艱選齋範糧蓋積(窪積窪顧糧簾製鹽鬱網) = 憲積製衊鑰襯鏇鏇製鏇 夢構鬱築齋齋齋鏇窪襯 (艱構餘廠觸膚醖襯襯範, 5.52) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用